The medtech industry is set for a transformative 2025, with trends like the growing competition in surgical robotics led by Intuitive Surgical’s da Vinci 5, a resurgence in M&A driven by companies like Boston Scientific and Stryker, and the rapid adoption of pulsed field ablation (PFA) technology revolutionizing atrial fibrillation treatment. Renal denervation (RDN) is also emerging as a potential multibillion-dollar market for hypertension, while economic uncertainties, trade tensions, and FDA staffing challenges under the new administration pose hurdles. Amid innovation and evolving dynamics, 2025 promises significant growth and disruption—will medtech rise to the challenge?
Previous ArticleWhat’s driving $4.9T in U.S. healthcare spending? (TechTarget)
Keep Reading
Add A Comment